Enhancing Medicare Coverage for Weight Loss Medications
The U.S. enhances Medicare's coverage on GLP-1 weight loss medications, reducing costs significantly for beneficiaries and improving health access.
CMS Announces Major Changes for Medicare Advantage and Part D Programs
Discover the key regulatory changes to Medicare Advantage and Part D programs impacting insurance carriers in 2027. Ensure your compliance strategies are up-to-date.
Boston Implements GLP-1 Coverage Restrictions for City Employees
Boston's plan to restrict GLP-1 drug coverage will save $11 million while managing rising healthcare costs for city employees. Learn more about this critical initiative.
Price Caps on Insulin Costs Improve Access for Medicare Beneficiaries
Discover how price caps on insulin under Medicare have improved access and affordability for beneficiaries, with costs decreasing significantly since 2019.
Addressing Rising Prescription Drug Costs: A Visit from Former President Trump
Explore how rising prescription drug costs and Medicaid cuts are impacting healthcare in Ohio ahead of Trump's visit to address these critical issues.
Eli Lilly's Medicare Drug Plan Update on Weight-Loss Medications
Eli Lilly's latest announcement on Medicare drug plans highlights the $50 cap on expenses for weight-loss medications. Learn more about the implications.
Medicare Prescription Payment Plan: A Vital Resource for Seniors
Discover how the Medicare Prescription Payment Plan benefits seniors with medication costs, yet struggles with low enrollment and awareness. Explore actionable solutions!
Rising Medicare Drug Prices: Impact on Costs and Strategies
Explore the impact of rising Medicare prices on prescription drugs. Understand challenges and proactive strategies for insurers and policymakers.
Medicare Part D Changes: Projected Cost Savings and Coverage Updates
Discover anticipated changes to Medicare Part D in 2026, focusing on cost savings and regulatory updates that enhance prescription drug coverage for beneficiaries.
Medicare Prescription Drug Plan Market Faces Financial Pressure and Rising Subsidies
Medicare Part D drug plan market under financial stress as taxpayers fund record-level subsidies to health insurers amid rising costs and program challenges.